aim2-inflammasome-modulator-therapy

Migration, Crosslink

📖

aim2-inflammasome-modulator-therapy

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-aim2-inflammasome-modu

📖 Wiki Page

therapeutic1647 wordssynced 2026-04-02

AIM2 Inflammasome Modulator Therapy for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">aim2-inflammasome-modulator-therapy</th>
</tr>
<tr>
<td class="label">Target Site</td>
<td>Therapeutic Approach</td>
</tr>
<tr>
<td class="label">AIM2 DNA binding (HIN domain)</td>
<td>Direct inhibitors blocking DNA binding</td>
</tr>
<tr>
<td class="label">AIM2 oligomerization</td>
<td>Oligomerization inhibitors</td>
</tr>
<tr>
<td class="label">AIM2-ASC interaction</td>
<td>Pyrin domain antagonists</td>
</tr>
<tr>
<td class="label">Caspase-1</td>
<td>Approved inhibitors (e.g., VX-765)</td>
</tr>
<tr>
<td class="label">IL-1β signaling</td>
<td>Anakinra, Canakinumab</td>
</tr>
<tr>
<td class="label">Gasdermin D</td>
<td>GSDMD inhibitors</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">AIM2-HIN antagonist</td>
<td>Blocks DNA binding to HIN domain</td>
</tr>
<tr>
<td class="label">AIM2 oligomerization inhibitor</td>
<td>Prevents AIM2 assembly</td>
</tr>
<tr>
<td class="label">Pyrin domain inhibitor</td>
<td>Blocks ASC interaction</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">VX-765 (Belnacasan)</td>
<td>Caspase-1</td>
</tr>
<tr>
<td class="label">Mcc950</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">Dapansutrile (OLT1177)</td>
<td>NLRP3</td>
</tr>
<t

...

AIM2 Inflammasome Modulator Therapy for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">aim2-inflammasome-modulator-therapy</th>
</tr>
<tr>
<td class="label">Target Site</td>
<td>Therapeutic Approach</td>
</tr>
<tr>
<td class="label">AIM2 DNA binding (HIN domain)</td>
<td>Direct inhibitors blocking DNA binding</td>
</tr>
<tr>
<td class="label">AIM2 oligomerization</td>
<td>Oligomerization inhibitors</td>
</tr>
<tr>
<td class="label">AIM2-ASC interaction</td>
<td>Pyrin domain antagonists</td>
</tr>
<tr>
<td class="label">Caspase-1</td>
<td>Approved inhibitors (e.g., VX-765)</td>
</tr>
<tr>
<td class="label">IL-1β signaling</td>
<td>Anakinra, Canakinumab</td>
</tr>
<tr>
<td class="label">Gasdermin D</td>
<td>GSDMD inhibitors</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">AIM2-HIN antagonist</td>
<td>Blocks DNA binding to HIN domain</td>
</tr>
<tr>
<td class="label">AIM2 oligomerization inhibitor</td>
<td>Prevents AIM2 assembly</td>
</tr>
<tr>
<td class="label">Pyrin domain inhibitor</td>
<td>Blocks ASC interaction</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">VX-765 (Belnacasan)</td>
<td>Caspase-1</td>
</tr>
<tr>
<td class="label">Mcc950</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">Dapansutrile (OLT1177)</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Original Indication</td>
</tr>
<tr>
<td class="label">Tranilast</td>
<td>Allergy, keloids</td>
</tr>
<tr>
<td class="label">Colchicine</td>
<td>Gout</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>Diabetes</td>
</tr>
<tr>
<td class="label">Statins</td>
<td>Hyperlipidemia</td>
</tr>
</table>

Overview

AIM2 (Absent in Melanoma 2) is a cytosolic DNA sensor that forms a critical inflammasome complex implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticobasal syndrome (CBS), and progressive supranuclear palsy (PSP)[@duan2021][@wu2020]. The AIM2 inflammasome detects foreign and host-derived DNA in the cytoplasm, triggering inflammatory cascades that contribute to chronic neuroinflammation and neuronal loss.

Therapeutic modulation of AIM2 represents a promising strategy across multiple neurodegenerative conditions, with ongoing research into small molecule inhibitors, natural compounds, and computational drug discovery approaches.

AIM2 Biology and Therapeutic Targets

Molecular Mechanism

The AIM2 inflammasome assembly follows a well-characterized pathway[@fernandes2009][@burchfield2019]:

DNA binding: The HIN domain (C-terminal) binds double-stranded DNA of bacterial, viral, or host origin in the cytoplasm

Oligomerization: Upon DNA binding, AIM2 undergoes oligomerization to form a signaling platform

ASC recruitment: The pyrin domain (N-terminal) recruits the adaptor protein ASC (PYCARD) through pyrin-pyrin domain interactions

Caspase-1 activation: ASC recruits pro-caspase-1, leading to its autocatalytic activation

Inflammasome formation: The assembled complex constitutes the AIM2 inflammasome

Downstream Effects

IL-1β/IL-18 processing: Active caspase-1 cleaves pro-IL-1β and pro-IL-18 to their active pro-inflammatory forms
[Pyroptosis](/mechanisms/pyroptosis): Gasdermin D cleavage leads to inflammatory cell death
Chronic neuroinflammation: Release of IL-1β and IL-18 amplifies neuroinflammation across multiple disease contexts

Therapeutic Target Sites

Evidence in Neurodegenerative Diseases

Alzheimer's Disease

AIM2 inflammasome activation significantly contributes to AD pathogenesis[@xia2020][@jiang2021]:

[Amyloid-beta](/proteins/amyloid-beta) accumulation triggers AIM2 inflammasome activation
AIM2 activation promotes production of pro-inflammatory cytokines that enhance Aβ accumulation
Creates a vicious cycle of inflammation and pathology
AIM2 inflammasome activation promotes [tau](/proteins/tau) hyperphosphorylation
AIM2 deficiency reduces tau pathology in model systems
Chronic microglial AIM2 activation drives neuroinflammation
IL-1β release contributes to synaptic dysfunction and cognitive decline

Therapeutic implication: AIM2 inhibitors could break the inflammation-aggregation cycle in AD.

Parkinson's Disease

AIM2 plays a critical role in PD progression[@chen2019]:

[Alpha-synuclein](/proteins/alpha-synuclein) aggregates activate AIM2 inflammasome
Inflammasome activation promotes α-synuclein propagation
Creates feed-forward loop between aggregation and inflammation
DNA damage in dopaminergic neurons activates AIM2
Mitochondrial stress triggers inflammasome assembly
Contributes to dopaminergic neuron loss in the substantia nigra

Therapeutic implication: AIM2 inhibition may protect dopaminergic neurons and slow disease progression.

Huntington's Disease

AIM2 inflammasome contributes significantly to HD pathogenesis[@kopalli2023]:

Mutant [huntingtin](/proteins/huntingtin-protein) triggers AIM2 activation
DNA damage from mutant huntingtin activates the inflammasome
AIM2 knockout extends lifespan in HD mouse models
Reduces neuronal loss and improves motor function

Therapeutic implication: AIM2 represents a promising target with strong preclinical proof-of-concept.

Amyotrophic Lateral Sclerosis (ALS)

C9orf72 repeat expansions may affect AIM2-mediated responses
Inflammasome activation in motor neurons contributes to neuroinflammation
Links innate immunity to motor neuron disease pathogenesis

Frontotemporal Dementia

AIM2 inflammasome activation has been reported in FTD[@liu2021]:

Elevated AIM2 expression in FTD brain
Contributes to neuroinflammation
May interact with tau pathology

Corticobasal Syndrome and Progressive Supranuclear palsy

Emerging evidence suggests AIM2 activation in tauopathies
CBS and PSP feature chronic neuroinflammation
AIM2 may represent a shared inflammatory mechanism

Small Molecule Inhibitors

Direct AIM2 Inhibitors

While no AIM2-specific inhibitors have reached clinical trials, several compounds are in various stages of development:

Indirect/Inflammasome-Targeted Approaches

More advanced compounds target downstream components:

Caspase-1 Inhibitors

Caspase-1 inhibitors block the common downstream effector of AIM2 and other inflammasomes:

VX-765 (Belnacasan): Oral prodrug, converted to active VRT-043198
PR-957: Selective Nlrp3 inflammasome inhibitor
Z-YVAD-FMK: Irreversible caspase-1 inhibitor (research use)

Clinical Considerations

Key challenges for AIM2-targeted therapy:

Blood-brain barrier penetration: Essential for CNS indications

Selectivity: Avoiding off-target effects on protective inflammasomes

Timing: Optimal intervention window in disease progression

Peripheral immunosuppression: Risk with systemic inflammasome inhibition

Natural Compounds

Several natural compounds have shown AIM2 inflammasome modulatory activity:

Polyphenols

Resveratrol: Inhibits AIM2 inflammasome activation via SIRT1
Curcumin: Modulates NF-κB and inflammasome pathways
Quercetin: Reduces IL-1β production and inflammasome activation
Epigallocatechin-3-gallate (EGCG): Anti-inflammatory effects in neurodegeneration

Flavonoids

Baicalein: Inhibits caspase-1 and IL-1β processing
Apigenin: Modulates inflammasome activation
Luteolin: Reduces neuroinflammation in models

Alkaloids

Berberine: Inhibits NLRP3 and potentially AIM2
Matrine: Suppresses inflammasome activation

Mechanism of Action

Natural compounds typically work through:

Antioxidant effects reducing oxidative stress-induced AIM2 activation
NF-κB pathway modulation
SIRT1 activation
Direct caspase-1 inhibition

Note: While promising in preclinical models, natural compounds generally lack clinical trial evidence for neurodegeneration specifically targeting AIM2.

Computational and Novel Approaches

Structure-Based Drug Design

The crystal structure of AIM2 HIN domain complexed with DNA (PDB: 3JCI) enables:

Virtual screening of compound libraries
Rational design of HIN-domain inhibitors
Simulation of DNA-binding site interactions
Pharmacophore modeling for lead optimization

AI/ML Approaches

Modern computational methods being applied:

Deep learning: AlphaFold2 for protein structure prediction
Molecular dynamics: Simulating AIM2-DNA interactions
Generative models: Designing novel AIM2-binding scaffolds
Virtual screening: Large-scale compound library analysis

Repurposing Opportunities

Drug repurposing candidates targeting AIM2 inflammasome:

Cross-Disease Relevance

Shared Mechanisms

AIM2 inflammasome activation represents a common pathway across neurodegenerative diseases:

Mermaid diagram (expand to render)

Biomarker Considerations

Potential biomarkers for AIM2-targeted therapy:

Peripheral: AIM2 expression in peripheral blood mononuclear cells
CSF: IL-1β, IL-18 levels
Imaging: PET ligands for neuroinflammation (TSPO)
Genetic: AIM2 polymorphisms as potential patient stratification markers

Combination Strategies

Rational combinations for AIM2-targeted therapy:

With anti-aggregation: Anti-Aβ, anti-α-syn, anti-tau therapies

With neuroprotection: BDNF mimetics, antioxidant compounds

With immune modulation: TREM2-targeting approaches

With gene therapy: AAV-mediated AIM2 knockdown

Therapeutic Development Pipeline

Preclinical Stage

AIM2 knockout mice: Available for target validation
AIM2-selective antibodies: In development
Small molecule libraries: High-throughput screening ongoing

Clinical Stage

No AIM2-specific inhibitors in clinical trials
Downstream targets (caspase-1, IL-1β) in clinical development
Repurposed drugs with inflammasome activity in trials

Challenges and Future Directions

Key challenges:

Brain penetration: Essential for neurodegenerative indications

Selectivity: Avoiding inhibition of protective inflammasome functions

Disease stage: Determining optimal intervention window

Patient selection: Identifying patients with AIM2-driven pathology

Emerging opportunities:

AIM2-ASC interaction inhibitors: Targeting protein-protein interface

Gene therapy: AAV-mediated AIM2 knockdown in specific cell types

Cell-type-specific delivery: Nanoparticle targeted to microglia

Biomarker development: Patient stratification for clinical trials

[Inflammasome Pathway](/mechanisms/inflammasome-pathway) — Overview of inflammasome signaling
[Neuroinflammation](/mechanisms/neuroinflammation) — Brain inflammation mechanisms
[Pyroptosis Signaling Pathway](/mechanisms/pyroptosis-signaling-pathway-neurodegeneration) — Inflammatory cell death
[DNA Sensing Pathways](/mechanisms/dna-sensing-pathways-neurodegeneration) — DNA sensor biology

[AIM2 Gene](/genes/aim2) — AIM2 gene page
[AIM2 Protein](/proteins/aim2-protein) — AIM2 protein page
[PYCARD/ASC](/genes/pycard) — Adaptor protein
[Caspase-1](/genes/casp1) — Effector protease
[NLRP3](/entities/nlrp3) — NLRP3 inflammasome

[NLRP3 Inflammasome Inhibitors](/therapeutics/nlrp3-inflammasome-inhibitors) — Related therapeutic approach
[IL-1 Beta Targeted Therapy](/therapeutics/il-1-beta-therapy) — Downstream cytokine targeting

[Alzheimer's Disease](/diseases/alzheimers-disease) — AD overview
[Parkinson's Disease](/diseases/parkinsons-disease) — PD overview
[Huntington's Disease](/diseases/huntingtons) — HD overview
[ALS](/diseases/amyotrophic-lateral-sclerosis) — ALS overview
[Frontotemporal Dementia](/diseases/frontotemporal-dementia) — FTD overview
[Corticobasal Syndrome](/diseases/corticobasal-syndrome) — CBS overview
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — PSP overview

References

[DeYoung KL et al, Cloning and characterization of AIM2 (1992)](https://pubmed.ncbi.nlm.nih.gov/1535431/)

[Burchfield JG et al, AIM2 in health and disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31867069/)

[Duan Y et al, Role of the AIM2 inflammasome in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/33912044/)

[Xia P et al, DNA sensor AIM2 inflammasome in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32161654/)

[Chen Y et al, Activation of AIM2 inflammasome enhances alpha-synuclein pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/31416468/)

[Kopalli SR et al, AIM2 deficiency extends lifespan in Huntington disease model (2023)](https://pubmed.ncbi.nlm.nih.gov/36893672/)

[Liu H et al, AIM2 inflammasome activation in frontotemporal dementia (2021)](https://pubmed.ncbi.nlm.nih.gov/34151806/)

[Robert K et al, Therapeutic potential of targeting AIM2 inflammasome (2019)](https://pubmed.ncbi.nlm.nih.gov/31267890/)

[Li H et al, Targeting AIM2 inflammasome for neurodegenerative disease treatment (2023)](https://pubmed.ncbi.nlm.nih.gov/36898421/)

[Fernandes-Alnemri T et al, AIM2 activates the inflammasome and cell death (2009)](https://pubmed.ncbi.nlm.nih.gov/19158675/)

[Jiang L et al, AIM2 inflammasome in tauopathy (2021)](https://pubmed.ncbi.nlm.nih.gov/33453487/)

[Wu PJ et al, AIM2 in neurodegenerative diseases: an emerging player (2020)](https://pubmed.ncbi.nlm.nih.gov/32767281/)

[Zhang L et al, DNA damage and AIM2 inflammasome in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36739789/)

[Morante J et al, Inflammasome activation in neurodegenerative diseases: the role of AIM2 (2022)](https://pubmed.ncbi.nlm.nih.gov/35628149/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.55 · Target: TREM2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.58 · Target: TREM2
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-aim2-inflammasome-modulator-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-aim2-inflammasome-modulator-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-2c18ae2c2cfa
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-aim2-inflammasome-modulator-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

53

Outgoing

105

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

aim2-inflammasome-modulator-therapy

AIM2 Inflammasome Modulator Therapy for Neurodegeneration

AIM2 Inflammasome Modulator Therapy for Neurodegeneration

Overview

AIM2 Biology and Therapeutic Targets

Molecular Mechanism

Downstream Effects

Therapeutic Target Sites

Evidence in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Amyotrophic Lateral Sclerosis (ALS)

Frontotemporal Dementia

Corticobasal Syndrome and Progressive Supranuclear palsy

Small Molecule Inhibitors

Direct AIM2 Inhibitors

Indirect/Inflammasome-Targeted Approaches

Caspase-1 Inhibitors

Clinical Considerations

Natural Compounds

Polyphenols

Flavonoids

Alkaloids

Mechanism of Action

Computational and Novel Approaches

Structure-Based Drug Design

AI/ML Approaches

Repurposing Opportunities

Cross-Disease Relevance

Shared Mechanisms

Biomarker Considerations

Combination Strategies

Therapeutic Development Pipeline

Preclinical Stage

Clinical Stage

Challenges and Future Directions

Cross-Linking and Related Pages

Related Mechanisms

Related Genes and Proteins

Related Therapeutics

Related Diseases

See Also

References

Related Hypotheses

💬 Discussion